| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
8-K/A: Regulation FD Disclosure
Readying Lonvo-z for Patients with HAE November 12, 2026 Exhibit 99.1 |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Readying Lonvo-z for Patients with HAE November 12, 2026 Exhibit 99.1 |
| 10 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date |
| 03 Nov 2026 |
Form 4: Leonard John M, Director
Sold 9,000 shares ($108K) |
| 02 Nov 2026 | 144 |
| 28 Oct 2026 |
Form 4: Marantz Jing L., EVP, Chief Medical Officer
Received 199,822 shares as a grant or award · Granted 275,061 Stock Option (right to buy) |
| 28 Oct 2026 |
Form 3: Marantz Jing L., EVP, Chief Medical Officer
No securities owned |
| 06 Oct 2026 |
Form 4: Dube Michael P, VP, Chief Accounting Officer
Sold 1,864 shares ($23.2K) |
| 05 Oct 2026 | 144 |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) |
| 04 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
$75 million funded upfront with an additional $325 million tied to milestones, providing |
| 24 Aug 2026 |
Form 4: Leonard John M, Director
Sold 19,890 shares ($251K) · Sold 2,785 shares ($36.2K) |
| 20 Aug 2026 | 144 |
| 07 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of Medicine |
| 24 Jul 2026 |
Form 4: Dulac Edward J Iii, EVP, Chief Financial Officer
Sold 8,111 shares ($91.2K) |
| 06 Jul 2026 |
Form 4: Dube Michael P, VP, Chief Accounting Officer
Sold 2,641 shares ($44.3K) |
Loading...